|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DEF6 |
Gene summary for DEF6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DEF6 | Gene ID | 50619 |
| Gene name | DEF6 guanine nucleotide exchange factor | |
| Gene Alias | IBP | |
| Cytomap | 6p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9H4E7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 50619 | DEF6 | LZE4T | Human | Esophagus | ESCC | 8.37e-09 | 2.79e-01 | 0.0811 |
| 50619 | DEF6 | LZE7T | Human | Esophagus | ESCC | 1.67e-04 | 3.11e-01 | 0.0667 |
| 50619 | DEF6 | LZE20T | Human | Esophagus | ESCC | 1.91e-04 | 2.66e-01 | 0.0662 |
| 50619 | DEF6 | LZE22D1 | Human | Esophagus | HGIN | 9.00e-04 | 1.63e-01 | 0.0595 |
| 50619 | DEF6 | LZE22T | Human | Esophagus | ESCC | 4.65e-02 | 3.06e-01 | 0.068 |
| 50619 | DEF6 | LZE24T | Human | Esophagus | ESCC | 3.29e-14 | 3.94e-01 | 0.0596 |
| 50619 | DEF6 | LZE21T | Human | Esophagus | ESCC | 2.86e-03 | 3.93e-01 | 0.0655 |
| 50619 | DEF6 | LZE6T | Human | Esophagus | ESCC | 1.65e-06 | 2.98e-01 | 0.0845 |
| 50619 | DEF6 | P1T-E | Human | Esophagus | ESCC | 1.52e-08 | 4.84e-01 | 0.0875 |
| 50619 | DEF6 | P2T-E | Human | Esophagus | ESCC | 7.67e-41 | 7.49e-01 | 0.1177 |
| 50619 | DEF6 | P4T-E | Human | Esophagus | ESCC | 6.58e-18 | 4.98e-01 | 0.1323 |
| 50619 | DEF6 | P5T-E | Human | Esophagus | ESCC | 1.30e-09 | 1.38e-01 | 0.1327 |
| 50619 | DEF6 | P8T-E | Human | Esophagus | ESCC | 1.53e-10 | 2.35e-01 | 0.0889 |
| 50619 | DEF6 | P9T-E | Human | Esophagus | ESCC | 2.48e-13 | 1.91e-01 | 0.1131 |
| 50619 | DEF6 | P10T-E | Human | Esophagus | ESCC | 6.24e-09 | 1.63e-01 | 0.116 |
| 50619 | DEF6 | P11T-E | Human | Esophagus | ESCC | 1.11e-07 | 4.22e-01 | 0.1426 |
| 50619 | DEF6 | P12T-E | Human | Esophagus | ESCC | 9.77e-18 | 4.44e-01 | 0.1122 |
| 50619 | DEF6 | P15T-E | Human | Esophagus | ESCC | 1.05e-17 | 3.73e-01 | 0.1149 |
| 50619 | DEF6 | P16T-E | Human | Esophagus | ESCC | 5.82e-20 | 4.06e-01 | 0.1153 |
| 50619 | DEF6 | P17T-E | Human | Esophagus | ESCC | 2.61e-02 | 2.28e-01 | 0.1278 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005105610 | Esophagus | ESCC | regulation of small GTPase mediated signal transduction | 157/8552 | 302/18723 | 1.55e-02 | 4.98e-02 | 157 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DEF6 | insertion | Frame_Shift_Ins | novel | c.131_132insC | p.His46ProfsTer2 | p.H46Pfs*2 | Q9H4E7 | protein_coding | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DEF6 | SNV | Missense_Mutation | novel | c.635N>T | p.Glu212Val | p.E212V | Q9H4E7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CC-A5UD-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| DEF6 | SNV | Missense_Mutation | c.1356A>C | p.Glu452Asp | p.E452D | Q9H4E7 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-MI-A75G-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DEF6 | SNV | Missense_Mutation | rs764573391 | c.914N>T | p.Ala305Val | p.A305V | Q9H4E7 | protein_coding | tolerated(0.84) | benign(0.138) | TCGA-RC-A6M6-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| DEF6 | SNV | Missense_Mutation | c.589N>T | p.Val197Leu | p.V197L | Q9H4E7 | protein_coding | tolerated(0.44) | benign(0.039) | TCGA-49-4487-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DEF6 | SNV | Missense_Mutation | rs764306600 | c.595N>T | p.Arg199Trp | p.R199W | Q9H4E7 | protein_coding | deleterious(0.01) | possibly_damaging(0.617) | TCGA-55-7910-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| DEF6 | SNV | Missense_Mutation | novel | c.541N>T | p.Val181Phe | p.V181F | Q9H4E7 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-95-7562-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
| DEF6 | SNV | Missense_Mutation | c.212A>G | p.Tyr71Cys | p.Y71C | Q9H4E7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-22-4604-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | iressa | PD | |
| DEF6 | SNV | Missense_Mutation | c.243G>T | p.Glu81Asp | p.E81D | Q9H4E7 | protein_coding | tolerated(0.19) | benign(0.062) | TCGA-43-6771-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| DEF6 | SNV | Missense_Mutation | novel | c.197N>T | p.Gln66Leu | p.Q66L | Q9H4E7 | protein_coding | deleterious(0) | benign(0.437) | TCGA-56-8628-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |